Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	€0.1310	0.00%	250
28/09/26	€0.1310	-3.68%	10,000
25/09/26	€0.1360	+11.48%	26,362
24/09/26	€0.1220	-14.08%	18,438
23/09/26	€0.1420	-11.25%	10,500

Delayed Quote Börse Stuttgart

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1525USD

Average target price

1.000USD

Spread / Average Target

+555.74%

Consensus

Annual profits - Rate of surprise

Company calendar

Delayed Börse Stuttgart 00:17:44 30/09/2026 HKT			5-day change	1st Jan Change
0.1310 ^EUR	0.00%		-18.12%	-36.41%

08-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-07	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

Market Cap	260M 230M 217M 197M 369M 24.96B 373M 2.61B 1B 12.75B 977M 955M 41.01B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	356M 314M 297M 270M 506M 34.18B 511M 3.57B 1.38B 17.45B 1.34B 1.31B 56.16B	EV / Sales 2026 *	-	EV / Sales 2027 *	9.89x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

08-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-07	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-09	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
01/11/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

08-15	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
08-07	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-09	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-03	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

Northwest Biotherapeutics, Inc. Stock Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Chart: Northwest Biotherapeutics, Inc.

Latest news: Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	-18.12%
Current month	-9.03%
1 month	-9.03%
3 months	-21.08%
6 months	-22.94%
Current year	-36.41%

1 week	0.12	0.18
1 month	0.12	0.19
Current year	0.1	0.38
1 year	0.1	0.38
3 years	0.1	0.93
5 years	0.1	2.18
10 years	0.1	2.18

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	0.00%	-18.12%	-	-	260M
WUXI APPTEC CO., LTD.	-0.70%	-4.35%	+56.10%	+86.42%	71.81B
ARGENX SE	+0.45%	-0.82%	+38.81%	+84.19%	60.06B
WUXI BIOLOGICS (CAYMAN) INC.	+0.19%	+0.94%	+36.97%	+21.32%	27.93B
INSMED INCORPORATED	-1.78%	-4.39%	-18.45%	+357.50%	25.7B
BIONTECH SE	-1.07%	-2.81%	-0.06%	-9.76%	24.89B
GENMAB A/S	+0.65%	+1.67%	+26.47%	-7.62%	20.92B
PHARMAESSENTIA CORPORATION	+3.46%	+3.91%	+158.90%	+337.81%	15.04B
EXELIXIS, INC.	-0.64%	+0.09%	+43.47%	+166.38%	14.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.91%	-4.56%	-2.71%	+506.41%	13.87B
Average	+0.46%	-0.92%	+37.72%	+171.41%	30.52B
Weighted average by Cap.	+0.08%	-1.74%	+38.05%	+127.98%

	2026 *	2027 *
Net sales	-	38.93M 34.36M 32.51M 29.48M 55.27M 3.74B 55.82M 390M 150M 1.91B 146M 143M 6.14B
Net income	-	-
Net Debt	96.08M 84.79M 80.22M 72.75M 136M 9.22B 138M 962M 371M 4.71B 361M 353M 15.15B	125M 110M 104M 94.61M 177M 11.99B 179M 1.25B 482M 6.12B 469M 459M 19.7B